Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome

Saved in:
Bibliographic Details
Published inClinical endocrinology (Oxford) Vol. 85; no. 4; pp. 671 - 673
Main Authors Sathyapalan, Thozhukat, Dakroury, Youssra, Ahmed, Lina, Elshewehy, Abeer M. M., Kilpatrick, Eric S., Coady, Anne-Marie, Atkin, Stephen L.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.10.2016
Wiley Subscription Services, Inc
Subjects
Body Mass Index
Cannabinoid Receptor Antagonists - therapeutic use
Cytokines - blood
Female
Hepatocyte Growth Factor - blood
Humans
Hypoglycemic Agents - therapeutic use
Insulin - therapeutic use
Insulin Resistance
Metformin - therapeutic use
Non-alcoholic Fatty Liver Disease - blood
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic Fatty Liver Disease - etiology
Obesity - blood
Obesity - complications
Piperidines - therapeutic use
Polycystic Ovary Syndrome - blood
Polycystic Ovary Syndrome - complications
Polycystic Ovary Syndrome - drug therapy
Pyrazoles - therapeutic use
Rimonabant
Online AccessGet full text

Cover

More Information
Bibliography:ArticleID:CEN13120
istex:FF374C66D9505BE2EB0797EA49A4A36B5E358EBB
ark:/67375/WNG-PS7K0Q5Z-F
SourceType-Other Sources-1
ObjectType-Correspondence-1
ObjectType-News-2
content type line 66
ObjectType-Article-3
ISSN:0300-0664
1365-2265
DOI:10.1111/cen.13120